Overview

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

Status:
Completed
Trial end date:
2020-03-27
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the potential of Topicort® (desoximetasone) Topical Spray, 0.25% to suppress hypothalmic pituitary adrenal axis function. The secondary objectives are to evaluate the efficacy parameters, pharmacokinetics and adverse event profile.
Phase:
Phase 4
Details
Lead Sponsor:
Taro Pharmaceuticals USA
Treatments:
Desoximetasone